CD47 and neoplasm: Additionally, several well-designed BsAbs have been created, such as IMM2902 for CD47-Her2, IMM0306 for CD47-D20, and IBI322 for CD47-PD-L1, which effectively inhibit the CD47-SIRPα signal and enhance tumor cell phagocytosis without significant impact on RBCs [[117], [118], [119], [120]] [[117], [118], [119], [120]] [[117], [118], [119], [120]].